zilganersen
zilganersen: developed by 1 company · 2 clinical trials tracked.
zilganersen evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could zilganersen → IONS affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| IONIS PHARMACEUTICALS INC (IONS) Alexander Disease | Phase 3 |
Clinical Trials (2)
Zilganersen Expanded Access Program for Individuals With Alexander Disease
A Phase 1-3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION373 in Patients With Alexander Disease
Primary endpoint: Percent Change from Baseline in the 10-Meter Walk Test (10MWT)
Frequently asked questions
Who is developing zilganersen?
zilganersen is being developed by IONIS PHARMACEUTICALS INC.
How many clinical trials involve zilganersen?
BioSniper tracks 2 clinical trials involving zilganersen.